PEACCEL at glance
November 29th, 2022
Making the world
We find the real drug
lead candidate by
capturing the synergistic effect of
We have developed the
innov’SAR AI platform
for our partners.
The innov’SAR core approach is interpolative, extrapolative and predicts out-of-the-box, not found in other state-of-the-art ML / DL. It can screen 1 Billion mutants per day.
PEACCEL is definitely the only company capable of fully capturing epistasis and predicting outside-the-box, we are ahead of competition especially in terms of “hit rate”.
Data Scientists in Life Sciences
Patent on proprietary molecules
Awards Winner in Artificial Intelligence for Life Sciences
Second technology patent by EPO
Contracts with key players in chemical industry
innov'SAR platform assembled for Protein Engineering for Drugs - Fixed Drugs Combinations (FDCs)
€2m competitive EU funds
First contracts with key pharmaceuticals companies
innov’SAR core launch
First technology patent delivered by EPO
Presence in Boston, MA, USA
Contract with FDA (USA)
Acquisition of a supercomputer : screening capacity >1Billion mutants/day
€1m seed money
Paris office, France
Artificial Intelligence, Machine Learning, Deep Learning, Biotechnology, Pharmaceuticals, Chemistry
PEACCEL is built around the 6 pillars - P6 - :
Platform | Publications | Patents | Partnership | Products | People
The company operates in Paris (France) and Cambridge (MA, USA).